Home
JournalsCollections
For Authors For Reviewers For Editorial Board Members
Article Processing Charges Open Access
Ethics Advertising Policy
Editorial Policy Resource Center
Company Information Contact Us
Publications > Journals > Gene Expression> Article Full Text
Review Article
OPEN ACCESS

Download PDF

Chronic Infection Considerations in Nonalcoholic Fatty Liver Disease Patients

  • Xiaoqian Ding1,#,
  • Zhenzhen Zhao2,#,
  • Shousheng Liu2,
  • Jie Zhang1,
  • Yong Zhou3,*  and
  • Yongning Xin2,* 
Gene Expression   2023;22(3):192-202

doi: 10.14218/GE.2022.00007

Received:

Revised:

Accepted:

Published online:

 Author information

Citation: Ding X, Zhao Z, Liu S, Zhang J, Zhou Y, Xin Y. Chronic Infection Considerations in Nonalcoholic Fatty Liver Disease Patients. Gene Expr. 2023;22(3):192-202. doi: 10.14218/GE.2022.00007.

Abstract

Nonalcoholic fatty liver disease (NAFLD) has become one of the most common and important chronic liver diseases worldwide. Some chronic infectious diseases are associated with the risk of NAFLD. These can induce abnormal glucose and lipid metabolism, insulin resistance, inflammatory activation and other responses, which increase the risk of progression of liver fibrosis. The present study describes the pathogenesis and management of NAFLD with chronic infectious diseases, such as hepatitis B virus, hepatitis C virus, Helicobacter pylori, and human immunodeficiency virus infections.

Keywords

Nonalcoholic fatty liver disease, Hepatitis B virus, Hepatitis C virus, Human immunodeficiency virus, Helicobacter pylori

Introduction

In recent years, the global incidence of nonalcoholic fatty liver disease (NAFLD) has increased (25%),1 and the incidence of hepatitis B virus (HBV, 25.6%),2 hepatitis C virus (HCV, 0.94%),3Helicobacter pylori (HP, 50%)4 and human immunodeficiency virus (HIV, 0.47%)5 infections remains high in the population. The risk factors of NAFLD have been extensively studied, such as advanced age, high body mass index (BMI), waist circumference, type-II diabetes, insulin resistance, lipodystrophy syndrome,6 obesity, male gender, hypertension, metabolic syndrome (MS), and abnormal biochemical indicators.7 Hepatic steatosis leads to changes in immune function. This may be due to the decrease in vitamin D levels that impairs innate immunity,8 and the increase in the number of Kupffer cells that induce a pro-inflammatory state.9 Thus, the interaction between NAFLD and infectious diseases in the occurrence and development of diseases needs to be further understood. The infections above can induce reactions, such as inflammatory activation, insulin resistance, abnormal glycolipid metabolism, and increased risk of hepatic fibrosis progression.6,7 The present study reviews the role of chronic infections, such as HBV, HCV, HIV and HP, in the occurrence and development of NAFLD, and its treatment options.

Hepatitis B virus

HBV infection causes a wide range of liver diseases, including acute hepatitis, chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Most adults who are infected with this virus recover, while 5–10% of infected subjects cannot clear the virus, and develop chronic hepatitis B (CHB). CHB infection is one of the most common co-existing liver diseases in NAFLD patients.10

Pathogenesis

As the two most common liver diseases, CHB and NAFLD interact with each other. The severity of steatosis is independently associated with the level of HBV DNA in blood.11 Hu et al. established a high-fat diet-induced NAFLD mouse model of HBV sustainable replication.12 They reported that liver steatosis inhibits HBV DNA replication, and that the replication of HBV does not alter the metabolism of lipids in mice. Compared to HBV mice, the serum hepatitis B e antigen, hepatitis B surface antigen (HBsAg), hepatitis B core antigen (HBcAg), and HBV DNA levels significantly decreased in HBV-infected NAFLD mice. Furthermore, Toll-like receptor (TLR) plays a significant role in the pathogenesis and progression of various chronic liver diseases (CLDs), including NAFLD, HCV, HBV, fibrosis and HCC.13 In HBV-transgenic mice, the TLR4/myeloid differentiation factor 88 (MyD88) pathway was stimulated in NAFLD, and this was induced by stearic acid steatosis. This activated the innate immune system, and released numerous proinflammatory cytokines (such as tumor necrosis factor [TNF]-α and interleukin [IL]6),14 inhibiting the HBV replication in CHB/NAFLD patients.

The effects of HBV on steatosis can be reflected at the mouse level, cellular level, and molecular level.12,14,15 HBV-infected HepG2 cells can stimulate the expression of genes related to cholesterol metabolism, and increase the hepatic cholesterol level through TLR2.15 A recent case-control study revealed that HBsAg seropositivity is associated with lower risk of developing NAFLD.16 Furthermore, the risk of HCC was higher in CHB patients with NAFLD, when compared to that in CHB patients without NAFLD.17 A study conducted in South Korea followed up 321 CHB patients for an average of 5.3 years to track the impact of NAFLD on HCC in CHB patients. It was found that the superimposed NAFLD (8.2%) was associated to CHB patients with a higher HCC risk, when compared to CHB patients without NAFLD (1.9%).17 In addition, NAFLD has effects on liver fibrosis and cirrhosis in HBV patients. A cohort study suggested that for CHB patients with virologically stationary CHB, persistent severe steatosis promotes the rapid progression of liver fibrosis, and that this is an independent risk factor for liver fibrosis.18 However, anti-HBs-Ab was not found to be associated with histological severity, while anti-HBC positivity was associated with cirrhosis in NAFLD patients, which in turn, may be associated with HCC and cirrhosis complications.19

Metabolic factors (obesity and type-II diabetes) are predisposing factors for CHB patients to develop NAFLD.16

Management

The diagnosis of HBV infection is based on the HBV DNA serum levels, and other serological markers, such as HBsAg, and antibodies to HBsAg (anti-HBs) and HBcAg (anti-HBc).20

Dietary adjustments combined with an appropriate increase in physical activity, including lifestyle adjustments, are recommended as the initial treatment for all HBV-positive NAFLD patients.21 Ceylan et al. reported that viral replication decreases in NAFLD patients with chronic HBV infection. However, NAFLD does not have an effect on the virologic response to entecavir and tenofovir treatment after six and 12 months of treatment.22 For patients with NAFLD, the virological responses were lower after 24, 48 and 96 weeks of entecavir treatment. It was hypothesized that this might be due to the reduced bioavailability of entecavir in fatty hepatocytes, and the reduced levels of cytochrome enzymes involved in drug metabolism.23 More studies need to be carried out to determine whether and how antiviral therapy has an impact on the development of NAFLD.

By the end of 2014, the HBV vaccine was introduced nationwide in 184 countries. The global coverage of three doses of HBV vaccine was estimated at 82% (vs. 1% in 1990).2 HBV is mainly transmitted vertically or horizontally, and neonatal immunoprophylaxis at birth is the most important and effective method to prevent it.24 HBV vaccines are used in at least 184 countries, with a three-dose coverage rate of 82%.2

In conclusion, HBV infection may reduce the risk of NAFLD. However, for NAFLD, in addition to common risk factors, the effect of other risk factors, and the use of entecavir and tenofovir on the disease course of NAFLD remains unclear, and requires further studies.

Hepatitis C virus

The worldwide prevalence of HCV infection approximates 1.6%, affecting approximately 115 million individuals.25 Globally, genotype 1 (G1) is the most common, and accounts for roughly one in two of all HCV infections in adults, followed by the G3, G2, G4, G6 and G5 genotypes.25 The average prevalence of NAFLD in HCV-infected individuals is approximately 55% (40–86%). The prevalence of NAFLD is significantly higher in HCV-infected individuals, when compared to that in non-HCV-infected individuals.26 Furthermore, the incidence of NAFLD is higher in patients infected with other genotypes of HCV, when compared to patients infected with non-genotype 3 HCV.27

Pathogenesis

Recent data has suggested that NAFLD is associated with fibrosis progression, which results from chronic HCV infection, and appears to be induced by insulin resistance and liver fat degeneration. HCV infection induces liver fatty degeneration and insulin resistance, liver fatty degeneration promotes the production of liver inflammation, and insulin resistance and liver inflammation lead to liver stellate cell activation, leading to liver fibrosis.27 Both steatosis and insulin resistance are independently associated with advanced liver fibrosis.28

HCV infection is associated with a variety of metabolic disorders, which are known as, hepatitis C-related metabolic disorder syndrome. This metabolic disorder is characterized by insulin resistance, hypocholesterolemia, hyperuricemia, and altered body fat distribution.29 HCV affects the development of NAFLD in various ways, in which insulin resistance and fat degeneration play an irreplaceable role. Furthermore, various factors can lead to insulin resistance, such as obesity, high BMI,30 and HCV.28 In addition, some inflammatory factors can cause insulin resistance, such as TNF-α and IL6.31 For obese subjects with viral genotype 1, the TNF-α and IL6 inflammation markers increase, and the insulin signaling pathway is reduced by increasing the expression of the suppressors of cytokine signaling (SOCS)-3 gene.31 For cases of chronic hepatitis C (CHC) infection, the incidence of insulin resistance was reported to be high (up to 80%).32 HCV infection with the G3 genotype is generally recognized as an independent risk factor for steatosis.33 The severity of hepatic steatosis correlates with the viral load, and the G3 genotype-associated steatosis is relieved after sustained virological response (SVR) with the antiviral treatment.33 HCV G3 genotype infection is associated with specific lipid accumulation. Hourioux et al. used an in vitro cell model to compare the lipid area of cell sections that produced the genotype G3 HCV core protein with the genotype 1a HCV core protein.34 It was found that the cumulative lipid droplet area was significantly greater in HCV G3 genotype cells, when compared to 1a genotype cells (p < 0.001).34 This may be attributed to the fact that phenylalanine residues have a higher affinity for lipids, when compared to tyrosine, and that these are specific to the G3 genotype.34 Furthermore, compared to the core protein of HCV-1b, the core protein of HCV-3a significantly upregulates fatty acid synthetase, which is an important enzyme for the synthesis of lipids.34 The HCV-1b core protein has previously been shown to inhibit both MTP and very low density lipoprotein (VLDL) secretion.35 This effect is more pronounced in the G3 genotype, and a recent study revealed that the MTP activity in the liver is significantly reduced in patients infected with the CHC G3 genotype, when compared to other genotypes (p = 0.004).36 CHC G3 genotype infection can reduce hepatic lipoprotein synthesis and release, and aggravate the degree of hepatic steatosis.37 In HCV cirrhosis patients, G3 genotype HCV has been independently associated with increased risk of HCC.37

Hepatocyte steatosis is the result of the combination of virus and host factors. The induction effects of different genotypes on steatosis are genotype specific, and the HCV genotype 3 virus has the strongest effect. Viral factors and HCV genotype 3 viral-induced steatosis are the most notable.38 For patients with non-genotype 3 HCV infections, NAFLD is mainly associated with host factors, such as BMI, obesity (especially visceral obesity),39 insulin resistance and type-II diabetes, which is known as, “metabolic steatosis”. For HCV-infected individuals, the prevalence and severity of fatty degeneration in patients with genotype 3 is much higher.40

HCV infection can affect liver steatosis through a variety of mechanisms (Fig. 1). Hemohemolytic oxygenase-1 (HO-1) is an important protective antioxidant defense enzyme. This is induced in some liver injury reactions, such as autoimmune hepatitis, CHB infection,41 and non-alcoholic steatohepatitis (NASH).42 It was reported that the HO-1 level decreases in the liver of HCV-infected subjects, and that this was considered to be part of the cause of HCV-induced liver damage.43 Furthermore, this may directly or indirectly interact with certain HCV proteins in the HO-1 induction pathway.44 Some studies have revealed that HCV core proteins promote lipid accumulation by activating sterol regulatory element binding protein-1 and -2,45 inhibiting the microsomal triglyceride transfer protein (MTP) activity35 and peroxisome proliferator-activated receptor (PPAR) expression, and promoting de novo lipid synthesis,46 depending on the specific genotype. Thus, the assembly, excretion and uptake of VLDL are impaired. The HCV core protein induces oxidative stress by upregulating SOCS-3, activating Kupffer cells, increasing proinflammatory cytokines (e.g., TNF-α), and increasing the reactive oxygen species, thereby promoting insulin resistance and liver fat degeneration, and further inhibiting the secretion of VLDL.47 Fat degeneration, which is common in CHC, plays an important role in the disease progression. Therefore, treating the liver fat degeneration is particularly important for HCV-infected patients with NAFLD. The presence of HCV infection and NAFLD can cause more severe interference with the steady state of essential minerals (zinc, selenium and copper) in the human body, thereby amplifying the oxidative stress and inflammation.48

Mechanism of HCV infection affecting the occurrence and development of NAFLD.
Fig. 1  Mechanism of HCV infection affecting the occurrence and development of NAFLD.

The red arrow indicates that the index level went up, and the blue arrow indicates that the index level went down. HCV, hepatitis C virus; HO-1, Hemohemolytic oxygenase-1; IL-6, interleukin-6; IR, insulin resistance; MTP, microsomal triglyceride transfer protein; NAFLD, nonalcoholic fatty liver disease; PPAR, peroxisome proliferator-activated receptor; ROS, reactive oxygen species; TNF-α, tumor necrosis factor; SOCS-3, suppressor of cytokine signalling 3; SREBP, Sterol regulatory element binding protein.

There are various risk-related factors associated with HCV infection in NAFLD patients, such as leptin, adiponectin, HO-1, some serological indicators (alanine aminotransferase [ALT]/aspartate aminotransferase [AST] ratio, fasting glucose, and triglyceride), and trace minerals (zinc, selenium and copper). Leptin is a protein secreted by fat cells, and is associated with insulin resistance and fat degeneration by increasing proinflammatory cytokines.49 Elena reported that adiponectin levels were higher in CHC patients, when compared to non-chronic hepatitis C patients.50 However, these lipid levels declined in patients with obesity, diabetes, CHC and NASH.51 Furthermore, recent studies have confirmed the significant correlation between liver fat degeneration and insulin resistance, and the decrease in lipid levels.52 As previously mentioned, HO-1 is involved in the pathogenesis, and its serological level may indicate HCV infection. Lin conducted a study in Taiwan, and tested 1,354 CHC patients. The results revealed that participants with NAFLD had higher levels of fasting glucose, ALT/AST, blood pressure and triglyceride, when compared to non-NAFLD participants.53 This suggests that for CHC patients, the increase in the serological indicators above may be a sign of NAFLD.

Management

The gold standard to diagnose HCV infection is the HCV RNA test and HCV genotype test.54 In addition, the total HCV antibodies in serum or plasma can be detected to help diagnose the HCV infection.55

For patients with HCV infection, there are various novel treatment plans for certain patients to improve SVR. The data revealed that the combination of IFN-α and ribavirin treatment in CHC patients, especially for patients with fatty degeneration greater than 30%, decreased the SVR rate.56 Furthermore, some in vitro studies have revealed that the use of statins reduces HCV replication.57 A recent prospective study evaluated the use of rosuvastatin in a joint IFN-α and ribavirin treatment, and revealed that the use of these drugs is associated with improved SVR rates, and reduced fat degeneration and fibros.58 Therefore, statins, as an auxiliary treatment for patients with fat degeneration and CHC, may appear as a viable option. However, larger prospective and randomized studies are needed to evaluate the treatment responses. When patients received the combined treatment that included vitamin E and IFN-α, the viral load significantly decreased.59 The use of antioxidant d-α-tocopherol has been shown to reduce the rate of fibrosis progression via the inhibition of stellate cell activation, thereby limiting the stellate cell-induced fibrogenesis in CHC patients.60 Gyanranjan et al. reported that after the treatment of Direct-acting Antiviral Agents (DAAs), the liver stiffness measurement (LSM) values decreased, and the controlled attenuation parameter (CAP) values (suggestive of hepatic steatosis) increased in CHC patients.61 Although the HCV was cured after the treatment with DAAs, follow-ups for the liver disease are still required, because CHC patients have a high risk of NAFLD.62

In summary, HCV infection increases the risk of NAFLD. Based on the above studies, in addition to conventional antiviral therapy for NAFLD patients infected with HCV, there are various new therapeutic drugs related to HCV infection in patients with NAFLD, but the actual efficacy of these drugs remains to be further studied.

Human immunodeficiency virus

Liver disease is the leading cause of morbidity and mortality in patients who live with HIV,63 while NASH, as a progressive stage of NAFLD, is a common disease with abnormal liver function.7 In a multicenter cohort conducted from 1999 to 2011, the liver disease mortality was 13%, making it the second leading non-AIDS-related cause of death in the study.64 According to Vodkin et al., HIV-associated NAFLD patients have a higher rate of steatohepatitis, and more significant liver damage.65 In view of this, the analysis of the association between NAFLD and HIV infection is particularly important for guidance in clinical practice.

Pathogenesis

Compared to non-HIV patients, excessive lipid accumulation in the liver in HIV patients is an extremely complex process with no single pathophysiological mechanism. HIV RNA levels are independently associated with multiple lipid markers, such as low-density lipoprotein, VLDL and triglyceride.66 Thus, HIV RNA levels are significantly correlated to blood lipid indicators, suggesting that HIV replication affects lipid metabolism.66

HIV infection can affect lipid metabolism through a variety of mechanisms (Fig. 2). Viral protein R (Vpr) is a 14-kDa protein encoded by all living primate lentiviruses, and plays a role in the viral life cycle.67 The pathogenesis of NAFLD with HIV infection may be gut microbial action, and the potentially induced pathogenesis of Vpr. The mechanisms of the gut microbiome in the pathogenesis of NAFLD possibly include the impairment of the gut barrier, which causes endotoxemia and the activation of TLRs, increase in short-chain fatty acids in obese adults, altered bile acid metabolism, reduced choline bioavailability, and subsequent changes in farnesoid X receptor (FXR) signaling.68 Importantly, HIV-1 infection can cause damage to the intestinal epithelium and dysregulation of the microbiota, and the microorganisms and their products can be transplanted from the lumen into systemic circulation.69

Mechanism of HIV infection affecting the occurrence and development of NAFLD.
Fig. 2  Mechanism of HIV infection affecting the occurrence and development of NAFLD.

The red arrow indicates that the index level went up, and the blue arrow indicates that the index level went down. DNL, de novo lipogenesis; FXR, farnesoid X receptor; GR, glucocorticoid receptor; LXR-α, liver X receptor-α; MTP, microsomal triglyceride transfer protein; NAFLD, nonalcoholic fatty liver disease; PPAR, peroxisome proliferator-activated receptor; VLDL-TG, very low density lipoprotein-triglyceride; Vpr, HIV-assisted protein.

Neeti et al. reported that Vpr genetically modified mice were more likely to have elevated liver triglyceride levels, and increased levels of ALT, choline, and alkaline phosphatase.70 Four pathways involved in hepatic lipid metabolism were disrupted in this mouse model that led to steatosis: (a) coactivation of the glucocorticoid receptor and co-inhibition of the PPARα to break down fat; (b) coactivation of hepatic X receptor α, which led to the increase in hepatic de novo neoadipogenesis (DNL); (c) the PPARα co-inhibition attenuated the hepatic fatty acid oxidation; (d) the PPARα co-inhibition or accumulation of long-chain fatty acids (derived from the DNL) in the microbody.71 Regardless of whether HIV-1 Vpr is produced or taken up by hepatocytes, this may disrupt hepatic lipid metabolism pathways, including lipid production and fatty acid oxidation, since Vpr replicates the HIV from host immune cells into the extracellular space. Due to the effects of Vpr on other tissues (for example, hyperlipidemia can lead to hepatic steatosis), and since Vpr can regulate a large number of liver genes involved in lipid and sterol metabolism, it was suggested that Vpr may play an important role in the development of other metabolic abnormalities.70

HIV infection has an important effect on the development of NAFLD, promoting fibrosis. The HIV enters cells through two co-receptors, CC chemokine receptor 5 (CCR5) and cysteine-X-cysteine receptor 4 (CXCR4). CCR5 and CXCR4 are expressed on activated hepatic stellate cells (HSCs), which are the central mediators of liver fibrosis.72 HIV can affect the activation of hepatic stellate cells, thereby causing collagen deposition and liver fibrosis.72 Furthermore, HIV infection and viral proteins promote the expression of type I collagen, and the secretion of proinflammatory collagen, while its envelope glycoprotein gp120 can affect both parenchymal and nonparenchymal cells, leading to inflammation and fibrosis.72,73 Moreover, the expression of gp120 can be increased by the migration of astrocytes mediated by CCR5, which in turn increases the secretion of monocyte chemoattractant protein-1 and the expression of IL6, resulting in an inflammatory state, and leading to chronic inflammation and damage of the surrounding liver cells. For individuals with HIV/HCV co-infection, gp120 can induce hepatocellular apoptosis by interacting with HCV proteins, such as core, E2, NS3/4A and NS5A.73In vitro models have revealed the enhanced activation and phosphorylation of signal transduction and transcription factor 1 (STAT1) after the co-stimulation of HCV-E2 and HIV-GP120.74 Considering the role of GP120 in hepatocyte steatosis and fibrosis, this injury pathway can be further investigated as a diagnostic and therapeutic target.

Patients may be at particularly high risk due to the aging population, severe presentation of common NAFLD risk factors, disturbances in the gut-liver axis, and additional effects of mechanisms related to HIV infection and antiretroviral therapy (ART).63 The secondary causes of fat degeneration are, as follows: ART, HCV, and alcohol.63

Management

Liver biopsy is rarely used for the diagnosis and evaluation of NAFLD in HIV carriers, while non-invasive fibrosis tests have been increasingly used.75,76 For HIV patients, transient elastography (TE) has an advantage over serum markers, because this is not affected by the HIV course or medication.77 The diagnostic value for liver fibrosis and steatosis was LSM ≥8.0 kPa78 and CAP ≥248 dB/m,79 respectively.

As mentioned above, for HIV-infected patients with NAFLD, the basic treatment is general treatment, such as nucleotide reverse transcriptase inhibitors (NRTIs).66 Studies have been conducted on the drug treatment of different pathways of fat accumulation, such as aramchol,80 tesamorelin,81 statins,82 and cenicriviroc.83 In a phase II clinical trial, aramchol has been shown to significantly reduce the hepatic fatty liver disease in the general population.80 However, more clinical trials are needed for tesamorelin, statins and cenicriviroc. Furthermore, most of the HIV-infected patients received combined antiretroviral therapy (cART), which achieved the basic inhibition of viral and immunoactivation of HIV, and the effects of HIV replication on lipid metabolism were eliminated.66

Different HIV drugs have different effects on liver steatosis. A number of early ART regimens, particularly NRTIs, have been associated with mitochondrial toxicity through multiple possible mechanisms. This results in mitochondrial toxicity and impaired fatty acid oxidation, which play an important role in the development of ectopic fat deposition and lipid dystrophy in tissues and organs,84 and contribute to the development of NAFLD through multiple pathways.85 Early NRTIs were usually associated with mitochondrial dysfunction, particularly stavudine, didanosine and zalcitabine, and to a lesser extent, zidovudine.86 Modern NRTs, such as tenofovir, have been rarely associated with significant mitochondrial dysfunction in clinical practice, and no relevant studies have reported that these promote the occurrence and development of NAFLD.86 Both stavudine and didanosine can cause liver damage through mitochondrial damage, oxidative stress, and microfouling fatty degeneration, and should be avoided in NAFLD.87 The chemokine receptor CCR2/CCR5 antagonist cenicriviroc, which has recently been shown to be effective in HIV treatment by inhibiting the entry of the virus, has also been shown to be effective in early trials for the treatment of NAFLD.83 Cenicriviroc may be a novel approach to treat or prevent HIV and NAFLD in patients with multiple NASH risk factors.83

Aramchol is a fatty acid-bile binder, which can reduce fatty acid synthesis, and increase fatty acid oxidation and liver cholesterol outflow. In a phase II trial, this has been shown to significantly reduce fatty liver in the general population.80 Tesamorelin is a growth hormone-releasing hormone that reduces visceral fat accumulation in HIV-infected individuals.88–90 In contrast to the GH itself, tesamorelin stimulates lipolysis by increasing endogenous GH, while maintaining negative feedback inhibition.88 Stanley et al. reported that tesamorelin can reduce the liver fat content in HIV-infected NAFLD patients, and it was further revealed that this can slow the progression of fibrosis, and improve liver inflammation.80,81 However, tesamorelin can reduce insulin sensitivity, leading to hyperglycaemia.91 Therefore, the security of using this in the long term remains uncertain, and this requires a lot of data to illustrate. A meta-analysis confirmed the fat-lowering effect of statins on HIV-infected patients treated with cART, showing that statins can significantly reduce total plasma cholesterol, triglyceride, and low-density lipoprotein cholesterol levels,92 and reduce adverse event rates.93 In addition, studies have revealed that HIV-infected patients treated with intensive statins have a lower cardiovascular disease risk.82

In conclusion, HIV infection can increase the risk of NAFLD. Furthermore, HIV infection can accelerate the progression of simple fat degeneration to NASH. Moreover, HIV treatment drugs may induce abnormal blood lipids, insulin resistance, and mitochondrial dysfunction, thereby promoting the development of NAFLD. Researchers and clinicians need to conduct extensive scientific and clinical studies to improve the efficiency of the non-invasive diagnosis and treatment of NAFLD in HIV patients.

HIV/HCV coinfection

Patients with HIV/HCV co-infection have a faster progression of liver fibrosis, and a higher rate of liver decompensation, when compared to HCV patients.94 HIV/HCV infection is associated with increased risk of hepatic depensation,95 high HCV viral load,96 elevated ALT levels,97 increased possibility of drug interactions,98 and changes in antiviral drug absorption.99

Helicobacter pylori

As it is known, approximately 50% of the global population is estimated to be infected by HP.100 HP is a Gram-negative and microaerophilic bacterium,101 which mainly causes gastrointestinal diseases in adults, including chronic gastritis, peptic ulcer, gastric muco-associated lymphoid tissue lymphoma, gastric cancer,102etc. HP-related samples have been detected in various liver disease biopsy samples, and studies have revealed that HP is associated with liver disease, such as hepatitis and hepatocarcinoma.103 Furthermore, the HP 16S rDNA was found in liver biopsies of NAFLD patients in 2008,104 and studies have confirmed that HP infection is significantly associated with NAFLD.105 Tian et al. reported that 47.82% of HP-infected individuals have NAFLD, and that HP infection is significantly correlated to NAFLD (OR = 1.2).105 Furthermore, the HP infection in individuals with dyslipidemia is significantly correlated with NAFLD (OR = 1.44). Although other studies have arrived at different conclusions,106 it is more likely that HP infection contributes to the progression of NAFLD.

Pathogenesis

HP infection can significantly increase the degree of steatosis in NAFLD mice, which is induced by high-fat diet.107 Furthermore, HP infection may be associated with iron deficiency.108 That is, the liver iron content was lower in HP-infected patients, when compared to uninfected patients.109 Although the mechanism of iron deposition in the liver of NASH patients has not been determined, iron may play an important role in at least part of the pathogenesis of NAFLD.110 The formation of hepcidin in NAFLD patients increases the iron load, leading to iron-induced oxidative damage to the intestinal mucosa,111 and this in turn increases the acid load.112 Studies have revealed that the increase in acid load can precipitate bile acid, and reduce the inhibition of HP in the bile, thereby increasing the risk of HP infection.112

HP has been considered to cause the pathogenesis of NAFLD by increasing insulin resistance, stimulating the release of inflammatory cytokines, and increasing intestinal permeability.113 Therefore, some scholars have speculated that the mechanism of HP that leads to NAFLD by inducing intestinal microbiota disorder is, as follows: HP invades the intestinal mucosa, leads to intestinal dysfunction, destroys the intestinal villi, increases intestinal permeability, promotes the secretion of bacterial endotoxin (specially lipopolysaccharide) through the hepatic portal vein, and promotes inflammatory reactions.109 In addition, HP can colonize both the stomach and duodenal epithelium, and the biliary epithelium.114

For patients infected with HP, the risk factors for NAFLD are adiponectin,115 leptin,116 diet structure, and infected strains.107 Circulating adiponectin levels are negatively correlated with HP infection.115 When adiponectin is reduced, the control of oxidation of free fatty acids into the mitochondria weakens, leading to free fatty acid accumulation in the cytoplasm.117 Leptin can reduce fat deposition in liver tissues by inhibiting the desaturation of liver stearoyl-CoA,118 and interfering with the insulin signaling.119 A study that involved 153 patients with dyspepsia revealed a significant negative association between HP infection and serum leptin levels (p < 0.001).116 Furthermore, the cytotoxin-associated gene A (CagA) negative population was significantly associated with the occurrence of NAFLD (OR = 1.30).120

Management

HP can be diagnosed through invasive tests, such as urease and molecular tests, and non-invasive methods, such as urea breath tests and fecal antigen tests.121

Standard triple therapy (PPI+ clarithromycin and amoxicillin/metronidazole) has been widely used as the first-line regimen. After the eradication of HP, the fasting plasma insulin level (p < 0.01) and homeostasis model assessment of insulin resistance (HOMA-IR) (p < 0.01) were significantly lower, when compared to those before treatment. This indicates that the HP eradication improved the insulin resistance, and that this might prevent the occurrence of MS and NAFLD.122,123 In the study conducted by Maharshi et al., after 24 weeks of treatment for HP positive patients, the liver CAP value exhibited a downward trend, but the difference was not statistically significant. Furthermore, the HP eradication had no significant effect on the changes in blood lipid indexes in NAFLD patients,124 which might be due to the small sample size. Further clinical studies are needed to explore the effect of HP eradication on NAFLD.

In conclusion, HP infection increases the risk of NAFLD. Furthermore, HP infection may induce the occurrence of NAFLD by changing the intestinal microecology, and choline, amino acid, and sugar metabolism. The relief and treatment effects of HP clearance in NAFLD need to be further verified.

Others

Hepatitis A virus (HAV), hepatitis D virus (HDV), and hepatitis E virus (HEV)

Compared to HBV and HCV, there is little evidence that HAV, HDV and HEV are involved in the development and progression of NAFLD.125

Human cytomegalovirus

Cytomegalovirus (CMV) is a beta-herpesvirus, which can infect a wide range of cell types. This can infect monocytes, adipocytes and endothelial cells, and is never completely cleared by the immune system, leading to lifelong infections.126 CMV infection in NAFLD patients is associated with gender and BMI.125 In patients with seropositive CMV, the incidence of MS was higher in normal-weight women, when compared to extremely obese women. Furthermore, a study revealed that the triglyceride and insulin levels were lower, and the HDL-cholesterol was higher in CMV-positive obese patients, when compared to CMV-negative patients.125 Moreover, studies have revealed that CMV can promote the development of NAFLD through de novo adipogenesis and oxidative stress.127,128 The treatment of NAFLD combined with CMV remains mainly as a symptomatic supportive treatment.129

In conclusion, it was suggested that CMV infection may increase the risk of NAFLD. However, more studies are needed to confirm this.

Adenovirus (ADV)

ADV belongs to the family of double-stranded DNA viruses, which are icosahedral in structure, have no envelope, and have diameters that range within 65–80 nanometers.130 There is evidence that human lipogenic adenovirus ADV36/ADV37 infection is associated with obesity, and that this is a causative factor for obesity in humans and animals.131 There are still a lot of speculations on the mechanisms involved.

First, studies have revealed that obese patients are more susceptible to ADV-36 infection, and that leptin levels are reduced in patients with ADV-36 infection.132,133 Furthermore, the seropositivity of ADV-36 is associated with better lipid and blood glucose control.134 Thus, it was speculated that ADV-36 may contribute to chronic inflammation, and the changes in lipid metabolism by reducing the leptin gene expression (as a feedback mechanism) and insulin sensitivity, increasing the glucose uptake, activating the lipogenesis and pro-inflammatory pathways in adipose tissues, and increasing the chemoattractor protein-1 levels in macrophages.135 Second, several molecular mechanisms that may be responsible for the “metabolic” effects of ADV-36 have been demonstrated. ADV-36 induces the upregulation of the cAMP, phosphatidylinositol 3-kinase (PI3K), and p38 signaling pathways, and the downregulation of Wnt10b, and increases the expression of CCAAT/enhancer binding protein-β and PPAR gam2, leading to lipid accumulation.136 Furthermore, the E4 Open Reading Frame (orf)-1 (E4ORF1) gene of the virus is required for ADV-36 to induce adipogenesis.136 At present, there are no approved treatments for ADV infection, and standard treatment relies on drugs approved to fight other viral infections.137

In conclusion, the possible mechanism of the involvement ADV-36 in NAFLD is to reduce the leptin gene expression and insulin sensitivity, increase the glucose uptake, and activate the lipogenesis and proinflammatory pathways in adipose tissues, leading to chronic inflammation, and affecting the lipid metabolism. However, these are only some of the assumptions based on previous studies, which need to be confirmed through a large number of population studies and basic studies.

Conclusion

Most chronic infections are significantly associated with the risk of NAFLD. With the exception of HBV, other chronic infections (HCV, HIV, HIV, CMV and ADV) are associated with increased risk of NAFLD. Chronic infection can induce reactions, such as abnormal glucose and lipid metabolism, insulin resistance, and inflammation activation, which increases the risk of liver fibrosis progression. At present, the molecular mechanism of chronic viral infections, such as CMV, and the risk of NAFLD need further studies, in order to provide guidance in clinical drug use and treatment. In carrying out antiviral and bacterial treatments, attention should be given to the changes in the condition of NAFLD, in order to achieve the best antiviral and antibacterial treatment effects, and minimize the adverse effects of drug treatments for NAFLD.

Abbreviations

ADV: 

adenovirus

ALT: 

alanine aminotransferase

ART: 

antiretroviral therapy

AST: 

aspartate aminotransferase

BMI: 

body mass index

CAP: 

controlled attenuation parameter

CHB: 

chronic hepatitis B

CMV: 

cytomegalovirus

DAAs: 

Direct-acting Antiviral Agents

HBsAg: 

hepatitis B surface antigen

HBV: 

hepatitis B virus

HCV: 

hepatitis C virus

HDL: 

high-density lipoprotein

HIV: 

human immunodeficiency virus

HO-1: 

Hemohemolytic oxygenase-1

IL-6: 

interleukin-6

IR: 

insulin resistance

LDL: 

low-density lipoprotein

MTP: 

microsomal triglyceride transfer protein

MS: 

metabolic syndrome

NAFLD: 

nonalcoholic fatty liver disease

NASH: 

non-alcoholic steatohepatitis

NRTIs: 

nucleotide reverse transcriptase inhibitors

PPAR: 

peroxisome proliferator-activated receptor

SOCS: 

suppressors of cytokine signaling

SVR: 

sustained virological response

TLR: 

toll-like receptor

TNF-α: 

tumor necrosis factor-α

TG: 

triglyceride

VLDL: 

very low density lipoprotein

Vpr: 

Viral protein R

Declarations

Acknowledgement

None to declare.

Funding

The study was supported by a grant from the National Natural Science Foundation of China (No. 32171277).

Conflict of interest

The authors have no conflict of interests related to this publication.

Authors’ contributions

Contributed to study concept and design (XYN and LSS), acquisition of the data (DXQ and ZZZ), assay performance and data analysis (ZY and ZJ), drafting of the manuscript (DXQ and ZZZ), critical revision of the manuscript (DXQ and ZZZ), supervision (DXQ).

References

  1. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018;24(7):908-922 View Article PubMed/NCBI
  2. Nelson NP, Easterbrook PJ, McMahon BJ. Epidemiology of hepatitis B virus infection and impact of vaccination on disease. Clin Liver Dis 2016;20(4):607-628 View Article PubMed/NCBI
  3. Casey JL, Feld JJ, MacParland SA. Restoration of HCV-specific immune responses with antiviral therapy: A case for DAA treatment in acute HCV infection. Cells 2019;8(4):317 View Article PubMed/NCBI
  4. Flores-Treviño S, Mendoza-Olazarán S, Bocanegra-Ibarias P, Maldonado-Garza HJ, Garza-González E. Helicobacter pylori drug resistance: Therapy changes and challenges. Expert Rev Gastroenterol Hepatol 2018;12(8):819-827 View Article PubMed/NCBI
  5. Bbosa N, Kaleebu P, Ssemwanga D. HIV subtype diversity worldwide. Current opinion in HIV and AIDS 2019;14(3):153-160 View Article PubMed/NCBI
  6. Bongiovanni M, Tordato F. Steatohepatitis in HIV-infected subjects: pathogenesis, clinical impact and implications in clinical management. Current HIV research 2007;5(5):490-498 View Article PubMed/NCBI
  7. Maurice JB, Patel A, Scott AJ, Patel K, Thursz M, Lemoine M. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection. AIDS (London, England) 2017;31(11):1621-1632 View Article PubMed/NCBI
  8. Lee SM, Jun DW, Cho YK, Jang KS. Vitamin D deficiency in non-alcoholic fatty liver disease: The chicken or the egg?. Clin Nutr 2017;36(1):191-197 View Article PubMed/NCBI
  9. Tang T, Sui Y, Lian M, Li Z, Hua J. Pro-inflammatory activated Kupffer cells by lipids induce hepatic NKT cells deficiency through activation-induced cell death. PloS One 2013;8(12):e81949 View Article PubMed/NCBI
  10. Shiffman ML. Approach to the patient with chronic hepatitis B and decompensated cirrhosis. Liver Int 2020;40(Suppl 1):22-26 View Article PubMed/NCBI
  11. Hui RWH, Seto WK, Cheung KS, Mak LY, Liu KSH, Fung J, et al. Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study. J Viral Hepat 2018;25(1):97-104 View Article PubMed/NCBI
  12. Hu D, Wang H, Wang H, Wang Y, Wan X, Yan W, et al. Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model. Hepat Int 2018;12(5):438-446 View Article PubMed/NCBI
  13. Plaza-Díaz J, Solís-Urra P, Rodríguez-Rodríguez F, Olivares-Arancibia J, Navarro-Oliveros M, Abadía-Molina F, et al. The gut barrier, intestinal microbiota, and liver disease: molecular mechanisms and strategies to manage. Int J Mol Sci 2020;21(21):8351 View Article PubMed/NCBI
  14. Suliman I, Abdelgelil N, Kassamali F, Hassanein TI. The effects of hepatic steatosis on the natural history of HBV infection. Clin Liver Dis 2019;23(3):433-450 View Article PubMed/NCBI
  15. Li YJ, Zhu P, Liang Y, Yin WG, Xiao JH. Hepatitis B virus induces expression of cholesterol metabolism-related genes via TLR2 in HepG2 cells. World J Gastroenterol 2013;19(14):2262-2269 View Article PubMed/NCBI
  16. Zhu L, Jiang J, Zhai X, Baecker A, Peng H, Qian J, et al. Hepatitis B virus infection and risk of non-alcoholic fatty liver disease: A population-based cohort study. Liver Int 2019;39(1):70-80 View Article PubMed/NCBI
  17. Lee YB, Ha Y, Chon YE, Kim MN, Lee JH, Park H, et al. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B. Clin Mol Hepatol 2019;25(1):52-64 View Article PubMed/NCBI
  18. Lung-Yi M, Wan-Hin HR, James F, Fen L, Ka-Ho WD, Ka-Shing C, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol 2020;73(4):800-806 View Article PubMed/NCBI
  19. Chan TT, Chan WK, Wong GL, Chan AW, Nik Mustapha NR, Chan SL, et al. Positive hepatitis B core antibody is associated with cirrhosis and hepatocellular carcinoma in nonalcoholic fatty liver disease. Am J Gastroenterol 2020;115(6):867-875 View Article PubMed/NCBI
  20. Coffin CS, Zhou K, Terrault NA. New and old biomarkers for diagnosis and management of chronic hepatitis B virus infection. Gastroenterology 2019;156(2):355-368.e353 View Article PubMed/NCBI
  21. Tafesh ZH, Verna EC. Managing nonalcoholic fatty liver disease in patients living with HIV. Curr Opin Infect Dis 2017;30(1):12-20 View Article PubMed/NCBI
  22. Ceylan B, Arslan F, Batırel A, Fincancı M, Yardımcı C, Fersan E, et al. Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir. Turk J Gastroenterol 2016;27(1):42-46 View Article PubMed/NCBI
  23. Leclercq I, Horsmans Y, Desager JP, Delzenne N, Geubel AP. Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation. J Hepatol 1998;28(3):410-416 View Article PubMed/NCBI
  24. Veronese P, Dodi I, Esposito S, Indolfi G. Prevention of vertical transmission of hepatitis B virus infection. World J Gastroenterol 2021;27(26):4182-4193 View Article PubMed/NCBI
  25. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61(Suppl 1):S45-57 View Article PubMed/NCBI
  26. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122(6):1649-1657 View Article PubMed/NCBI
  27. Adinolfi LE, Rinaldi L, Guerrera B, Restivo L, Marrone A, Giordano M, et al. NAFLD and NASH in HCV infection: prevalence and significance in hepatic and extrahepatic manifestations. Int J Mol Sci 2016;17(6):803 View Article PubMed/NCBI
  28. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008;134(2):416-423 View Article PubMed/NCBI
  29. Lonardo A, Adinolfi LE, Restivo L, Ballestri S, Romagnoli D, Baldelli E, et al. Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. World J Gastroenterol 2014;20(23):7089-7103 View Article PubMed/NCBI
  30. Cua IH, Hui JM, Kench JG, George J. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology (Baltimore, Md) 2008;48(3):723-731 View Article PubMed/NCBI
  31. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006;55(4):529-535 View Article PubMed/NCBI
  32. Vidali M, Tripodi MF, Ivaldi A, Zampino R, Occhino G, Restivo L, et al. Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. J Hepatol 2008;48(3):399-406 View Article PubMed/NCBI
  33. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Malé PJ, Mentha G, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000;33(1):106-115 View Article PubMed/NCBI
  34. Hourioux C, Patient R, Morin A, Blanchard E, Moreau A, Trassard S, et al. The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. Gut 2007;56(9):1302-1308 View Article PubMed/NCBI
  35. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chrétien Y, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB 2002;16(2):185-194 View Article PubMed/NCBI
  36. Mirandola S, Realdon S, Iqbal J, Gerotto M, Dal Pero F, Bortoletto G, et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 2006;130(6):1661-1669 View Article PubMed/NCBI
  37. Nkontchou G, Ziol M, Aout M, Lhabadie M, Baazia Y, Mahmoudi A, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. Journal of viral hepatitis 2011;18(10):e516-522 View Article PubMed/NCBI
  38. Cheng FK, Torres DM, Harrison SA. Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy?. J Viral Hepat 2014;21(1):1-8 View Article PubMed/NCBI
  39. Hickman IJ, Powell EE, Prins JB, Clouston AD, Ash S, Purdie DM, et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepat 2003;39(6):1042-1048 View Article PubMed/NCBI
  40. Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G. Hepatitis C and steatosis: a reappraisal. J Viral Hepat 2006;13(2):73-80 View Article PubMed/NCBI
  41. Liu B, Wen X, Huang C, Wei Y. Unraveling the complexity of hepatitis B virus: from molecular understanding to therapeutic strategy in 50 years. Int J Biochem Cell Biol 2013;45(9):1987-1996 View Article PubMed/NCBI
  42. Malaguarnera L, Madeddu R, Palio E, Arena N, Malaguarnera M. Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. J Hepat 2005;42(4):585-591 View Article PubMed/NCBI
  43. Wen F, Brown KE, Britigan BE, Schmidt WN. Hepatitis C core protein inhibits induction of heme oxygenase-1 and sensitizes hepatocytes to cytotoxicity. Cell Biol Toxicol 2008;24(2):175-188 View Article PubMed/NCBI
  44. Abdalla MY, Mathahs MM, Ahmad IM. Reduced heme oxygenase-1 expression in steatotic livers infected with hepatitis C virus. European journal of internal medicine 2012;23(7):649-655 View Article PubMed/NCBI
  45. Oem JK, Jackel-Cram C, Li YP, Zhou Y, Zhong J, Shimano H, et al. Activation of sterol regulatory element-binding protein 1c and fatty acid synthase transcription by hepatitis C virus non-structural protein 2. J Gen Virol 2008;89(Pt 5):1225-1230 View Article PubMed/NCBI
  46. de Gottardi A, Pazienza V, Pugnale P, Bruttin F, Rubbia-Brandt L, Juge-Aubry CE, et al. Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. Aliment Pharmacol Ther 2006;23(1):107-114 View Article PubMed/NCBI
  47. Alberstein M, Zornitzki T, Zick Y, Knobler H. Hepatitis C core protein impairs insulin downstream signalling and regulatory role of IGFBP-1 expression. J Viral Hepat 2012;19(1):65-71 View Article PubMed/NCBI
  48. Guo CH, Chen PC, Ko WS. Status of essential trace minerals and oxidative stress in viral hepatitis C patients with nonalcoholic fatty liver disease. Int J Med Sci 2013;10(6):730-737 View Article PubMed/NCBI
  49. Widjaja A, Wedemeyer H, Tillmann HL, Horn R, Ockenga J, Jaeckel E, et al. Hepatitis C and the leptin system: bound leptin levels are elevated in patients with hepatitis C and decrease during antiviral therapy. Scand J Gastroenterol 2001;36(4):426-431 View Article PubMed/NCBI
  50. Canavesi E, Porzio M, Ruscica M, Rametta R, Macchi C, Pelusi S, et al. Increased circulating adiponectin in males with chronic HCV hepatitis. Eur J Intern Med 2015;26(8):635-639 View Article PubMed/NCBI
  51. Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol 2006;101(11):2629-2640 View Article PubMed/NCBI
  52. Anty R, Gelsi E, Giudicelli J, Mariné-Barjoan E, Gual P, Benzaken S, et al. Glucose intolerance and hypoadiponectinemia are already present in lean patients with chronic hepatitis C infected with genotype non-3 viruses. Eur J Gastroenterol Hepatol 2007;19(8):671-677 View Article PubMed/NCBI
  53. Lin MS, Lin HS, Chung CM, Lin YS, Chen MY, Chen PH, et al. Serum aminotransferase ratio is independently correlated with hepatosteatosis in patients with HCV: a cross-sectional observational study. BMJ Open 2015;5(9):e008797 View Article PubMed/NCBI
  54. Wilkins T, Akhtar M, Gititu E, Jalluri C, Ramirez J. Diagnosis and management of hepatitis C. Am Fam Physician 2015;91(12):835-842 View Article PubMed/NCBI
  55. Chevaliez S. Strategies for the improvement of HCV testing and diagnosis. Expert Rev Anti Infect Ther 2019;17(5):341-347 View Article PubMed/NCBI
  56. Harrison SA, Brunt EM, Qazi RA, Oliver DA, Neuschwander-Tetri BA, Di Bisceglie AM, et al. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005;3(6):604-609 View Article PubMed/NCBI
  57. Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA 2005;102(7):2561-2566 View Article PubMed/NCBI
  58. Malaguarnera M, Vacante M, Russo C, Gargante MP, Giordano M, Bertino G, et al. Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with α-interferon and ribavirin: Rosuvastatin reduces NAFLD in HCV patients. Hepat Mon 2011;11(2):92-98 View Article PubMed/NCBI
  59. Look MP, Gerard A, Rao GS, Sudhop T, Fischer HP, Sauerbruch T, et al. Interferon/antioxidant combination therapy for chronic hepatitis C—a controlled pilot trial. Antiviral Res 1999;43(2):113-122 View Article PubMed/NCBI
  60. Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997;113(4):1069-1073 View Article PubMed/NCBI
  61. Rout G, Nayak B, Patel AH, Gunjan D, Singh V, Kedia S, et al. Therapy with oral directly acting agents in hepatitis C infection is associated with reduction in fibrosis and increase in hepatic steatosis on transient elastography. J Clin Exp Hepatol 2019;9(2):207-214 View Article PubMed/NCBI
  62. Cespiati A, Petta S, Lombardi R, Di Marco V, Calvaruso V, Bertelli C, et al. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP). Dig Liver Dis 2021;53(10):1301-1307 View Article PubMed/NCBI
  63. Verna EC. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV. Lancet Gastroenterol Hepatol 2017;2(3):211-223 View Article PubMed/NCBI
  64. Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 2014;384(9939):241-248 View Article PubMed/NCBI
  65. Vodkin I, Valasek MA, Bettencourt R, Cachay E, Loomba R. Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study. Aliment Pharmacol Ther 2015;41(4):368-378 View Article PubMed/NCBI
  66. El-Sadr WM, Mullin CM, Carr A, Gibert C, Rappoport C, Visnegarwala F, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med 2005;6(2):114-121 View Article PubMed/NCBI
  67. Nodder SB, Gummuluru S. Illuminating the role of Vpr in HIV infection of myeloid cells. Front Immunol 2019;10:1606 View Article PubMed/NCBI
  68. Sharpton SR, Ajmera V, Loomba R. Emerging role of the gut microbiome in nonalcoholic fatty liver disease: from composition to function. Clin Gastroenterol Hepatol 2019;17(2):296-306 View Article PubMed/NCBI
  69. Dillon SM, Frank DN, Wilson CC. The gut microbiome and HIV-1 pathogenesis: a two-way street. AIDS 2016;30(18):2737-2751 View Article PubMed/NCBI
  70. Agarwal N, Iyer D, Gabbi C, Saha P, Patel SG, Mo Q, et al. HIV-1 viral protein R (Vpr) induces fatty liver in mice via LXRα and PPARα dysregulation: implications for HIV-specific pathogenesis of NAFLD. Sci Rep 2017;7(1):13362 View Article PubMed/NCBI
  71. Améen C, Edvardsson U, Ljungberg A, Asp L, Akerblad P, Tuneld A, et al. Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver. J Biol Chem 2005;280(2):1224-1229 View Article PubMed/NCBI
  72. Tuyama AC, Hong F, Saiman Y, Wang C, Ozkok D, Mosoian A, et al. Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Hepatology 2010;52(2):612-622 View Article PubMed/NCBI
  73. Blackard JT, Sherman KE. HCV/ HIV co-infection: time to re-evaluate the role of HIV in the liver?. J Viral Hepat 2008;15(5):323-330 View Article PubMed/NCBI
  74. Balasubramanian A, Ganju RK, Groopman JE. Signal transducer and activator of transcription factor 1 mediates apoptosis induced by hepatitis C virus and HIV envelope proteins in hepatocytes. J Infect Dis 2006;194(5):670-681 View Article PubMed/NCBI
  75. Perazzo H, Cardoso SW, Yanavich C, Nunes EP, Morata M, Gorni N, et al. Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono-infection under long-term combined antiretroviral therapy. J Int AIDS Soc 2018;21(11):e25201 View Article PubMed/NCBI
  76. Buzzetti E, Lombardi R, De Luca L, Tsochatzis EA. Noninvasive assessment of fibrosis in patients with nonalcoholic fatty liver disease. Int J Endocrinol 2015;2015:343828 View Article PubMed/NCBI
  77. Tsochatzis EA, Castera L. Assessing liver disease in HIV-HCV coinfected patients. Curr Opin HIV AIDS 2015;10(5):316-322 View Article PubMed/NCBI
  78. Koehler EM, Plompen EP, Schouten JN, Hansen BE, Darwish Murad S, Taimr P, et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. Hepatology 2016;63(1):138-147 View Article PubMed/NCBI
  79. Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Lédinghen V, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol 2017;66(5):1022-1030 View Article PubMed/NCBI
  80. Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA 2014;312(4):380-389 View Article PubMed/NCBI
  81. Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV 2019;6(12):e821-e830 View Article PubMed/NCBI
  82. Ou HT, Chang KC, Li CY, Yang CY, Ko NY. Intensive statin regimens for reducing risk of cardiovascular diseases among human immunodeficiency virus-infected population: A nation-wide longitudinal cohort study 2000-2011. Int J Cardiol 2017;230:592-598 View Article PubMed/NCBI
  83. Thompson M, Saag M, DeJesus E, Gathe J, Lalezari J, Landay AL, et al. A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus. AIDS 2016;30(6):869-878 View Article PubMed/NCBI
  84. Gardner K, Hall PA, Chinnery PF, Payne BA. HIV treatment and associated mitochondrial pathology: review of 25 years of in vitro, animal, and human studies. Toxicol Pathol 2014;42(5):811-822 View Article PubMed/NCBI
  85. Wei Y, Rector RS, Thyfault JP, Ibdah JA. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol 2008;14(2):193-199 View Article PubMed/NCBI
  86. Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 2001;276(44):40847-40857 View Article PubMed/NCBI
  87. Núñez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 2010;52(3):1143-1155 View Article PubMed/NCBI
  88. Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab 2011;96(1):150-158 View Article PubMed/NCBI
  89. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357(23):2359-2370 View Article PubMed/NCBI
  90. Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010;95(9):4291-4304 View Article PubMed/NCBI
  91. Audsley J, Sasadeusz J, Lewin SR. Tesamorelin, liver fat, and NAFLD in the setting of HIV. Lancet HIV 2019;6(12):e808-e809 View Article PubMed/NCBI
  92. Nakanjako D, Ssinabulya I, Nabatanzi R, Bayigga L, Kiragga A, Joloba M, et al. Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial. Trop Med Int Health 2015;20(3):380-390 View Article PubMed/NCBI
  93. Gili S, Grosso Marra W, D’Ascenzo F, Lonni E, Calcagno A, Cannillo M, et al. Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis. Eur Heart J 2016;37(48):3600-3609 View Article PubMed/NCBI
  94. Lo Re V, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med 2014;160(6):369-379 View Article PubMed/NCBI
  95. Klein MB, Althoff KN, Jing Y, Lau B, Kitahata M, Lo Re V, et al. Risk of end-stage liver disease in HIV-viral hepatitis coinfected persons in North America from the early to modern antiretroviral therapy eras. Clin Infect Dis 2016;63(9):1160-1167 View Article PubMed/NCBI
  96. Mena A, Meijide H, Rodríguez-Osorio I, Castro A, Poveda E. Liver-related mortality and hospitalizations attributable to chronic hepatitis C virus coinfection in persons living with HIV. HIV Med 2017;18(9):685-689 View Article PubMed/NCBI
  97. Behzadpour D, Ahmadi Vasmehjani A, Mousavi Nasab SD, Ahmadi NA, Baharlou R. Impact of HIV infection in patients infected with chronic HCV (genotypes 1a and 3a): virological and clinical changes. Pathog Glob Health 2016;110(7-8):310-315 View Article PubMed/NCBI
  98. Garrison KL, German P, Mogalian E, Mathias A. The drug-drug interaction potential of antiviral agents for the treatment of chronic hepatitis C infection. Drug Metab Dispos 2018;46(8):1212-1225 View Article PubMed/NCBI
  99. Regazzi M, Maserati R, Villani P, Cusato M, Zucchi P, Briganti E, et al. Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects. Antimicrob Agents Chemother 2005;49(2):643-649 View Article PubMed/NCBI
  100. Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology 2009;136(6):1863-1873 View Article PubMed/NCBI
  101. Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev 1997;10(4):720-741 View Article PubMed/NCBI
  102. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006;19(3):449-490 View Article PubMed/NCBI
  103. Pellicano R, Ménard A, Rizzetto M, Mégraud F. Helicobacter species and liver diseases: association or causation?. Lancet Infect Dis 2008;8(4):254-260 View Article PubMed/NCBI
  104. Cindoruk M, Cirak MY, Unal S, Karakan T, Erkan G, Engin D, et al. Identification of Helicobacter species by 16S rDNA PCR and sequence analysis in human liver samples from patients with various etiologies of benign liver diseases. Eur J Gastroenterol Hepatol 2008;20(1):33-36 View Article PubMed/NCBI
  105. Jiang T, Chen X, Xia C, Liu H, Yan H, Wang G, et al. Association between Helicobacter pylori infection and non-alcoholic fatty liver disease in North Chinese: a cross-sectional study. Sci Rep 2019;9(1):4874 View Article PubMed/NCBI
  106. Fan N, Peng L, Xia Z, Zhang L, Wang Y, Peng Y. Helicobacter pylori infection is not associated with non-alcoholic fatty liver disease: A cross-sectional study in China. Front Microbiol 2018;9:73 View Article PubMed/NCBI
  107. He C, Cheng D, Wang H, Wu K, Zhu Y, Lu N. Helicobacter pylori infection aggravates diet-induced nonalcoholic fatty liver in mice. Clin Res Hepatol Gastroenterol 2018;42(4):360-367 View Article PubMed/NCBI
  108. Barabino A. Helicobacter pylori-related iron deficiency anemia: a review. Helicobacter 2002;7(2):71-75 View Article PubMed/NCBI
  109. Sumida Y, Kanemasa K, Imai S, Mori K, Tanaka S, Shimokobe H, et al. Helicobacter pylori infection might have a potential role in hepatocyte ballooning in nonalcoholic fatty liver disease. J Gastroenterol 2015;50(9):996-1004 View Article PubMed/NCBI
  110. Sumida Y, Yoshikawa T, Okanoue T. Role of hepatic iron in non-alcoholic steatohepatitis. Hepatol Res 2009;39(3):213-222 View Article PubMed/NCBI
  111. Shirase T, Mori K, Okazaki Y, Itoh K, Yamamoto M, Tabuchi M, et al. Suppression of SLC11A2 expression is essential to maintain duodenal integrity during dietary iron overload. Am J Pathol 2010;177(2):677-685 View Article PubMed/NCBI
  112. Ahlquist DA, Dozois RR, Zinsmeister AR, Malagelada JR. Duodenal prostaglandin synthesis and acid load in health and in duodenal ulcer disease. Gastroenterology 1983;85(3):522-528 View Article PubMed/NCBI
  113. Li M, Shen Z, Li YM. Potential role of Helicobacter pylori infection in nonalcoholic fatty liver disease. World J Gastroenterol 2013;19(41):7024-7031 View Article PubMed/NCBI
  114. Figura N, Franceschi F, Santucci A, Bernardini G, Gasbarrini G, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Helicobacter 2010;15 Suppl 1:60-68 View Article PubMed/NCBI
  115. Ando T, Ishikawa T, Takagi T, Imamoto E, Kishimoto E, Okajima A, et al. Impact of Helicobacter pylori eradication on circulating adiponectin in humans. Helicobacter 2013;18(2):158-164 View Article PubMed/NCBI
  116. Hemmasi G, Zamani F, Khonsari M, Sohrabi M, Abdollahi N, Ajdarkosh H. Association between helicobacter pylori and serum leptin in Iranian dyspeptic patients. Middle East J Dig Dis 2013;5(3):158-162 View Article PubMed/NCBI
  117. Capeau J. Insulin resistance and steatosis in humans. Diabetes Metab 2008;34(6 Pt 2):649-657 View Article PubMed/NCBI
  118. Ding X, Saxena NK, Lin S, Xu A, Srinivasan S, Anania FA. The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol 2005;166(6):1655-1669 View Article PubMed/NCBI
  119. Hennige AM, Stefan N, Kapp K, Lehmann R, Weigert C, Beck A, et al. Leptin down-regulates insulin action through phosphorylation of serine-318 in insulin receptor substrate 1. FASEB J 2006;20(8):1206-1208 View Article PubMed/NCBI
  120. Kang SJ, Kim HJ, Kim D, Ahmed A. Association between cagA negative Helicobacter pylori status and nonalcoholic fatty liver disease among adults in the United States. PLoS One 2018;13(8):e0202325 View Article PubMed/NCBI
  121. Skrebinska S, Mégraud F, Bessède E. Diagnosis of Helicobacter pylori infection. Helicobacter 2018;23(Suppl 1):e12515 View Article PubMed/NCBI
  122. Abenavoli L, Milic N, Masarone M, Persico M. Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori. Med Hypotheses 2013;81(5):913-915 View Article PubMed/NCBI
  123. Dogan Z, Sarikaya M, Ergul B, Filik L. The effect of Helicobacter pylori eradication on insulin resistance and HbA1c level in people with normal glucose levels: a prospective study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015;159(2):242-245 View Article PubMed/NCBI
  124. Maharshi V, Gupta P, Kumar VL, Upadhyay AD, Das P, Yadav R, et al. Effect of Helicobacter pylori-eradication therapy on hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomized-controlled pilot study. Gastroenterol Rep (Oxf) 2020;8(2):104-110 View Article PubMed/NCBI
  125. Boeckmans J, Rombaut M, Demuyser T, Declerck B, Piérard D, Rogiers V, et al. Infections at the nexus of metabolic-associated fatty liver disease. Arch Toxicol 2021;95(7):2235-2253 View Article PubMed/NCBI
  126. Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004;4(12):725-738 View Article PubMed/NCBI
  127. Boeckmans J, Natale A, Buyl K, Rogiers V, De Kock J, Vanhaecke T, et al. Human-based systems: Mechanistic NASH modelling just around the corner?. Pharmacol Res 2018;134:257-267 View Article PubMed/NCBI
  128. Combs JA, Norton EB, Saifudeen ZR, Bentrup KHZ, Katakam PV, Morris CA, et al. Human cytomegalovirus alters host cell mitochondrial function during acute infection. J Virol 2020;94(2):e01183-19 View Article PubMed/NCBI
  129. Khiatah B, Nasrollah L, Covington S, Carlson D. Nonalcoholic fatty liver disease as a risk factor for cytomegalovirus hepatitis in an immunocompetent patient: A case report. World J Clin Cases 2021;9(6):1455-1460 View Article PubMed/NCBI
  130. Esposito S, Preti V, Consolo S, Nazzari E, Principi N. Adenovirus 36 infection and obesity. J Clin Virol 2012;55(2):95-100 View Article PubMed/NCBI
  131. Trovato FM, Catalano D, Garozzo A, Martines GF, Pirri C, Trovato GM. ADV36 adipogenic adenovirus in human liver disease. World J Gastroenterol 2014;20(40):14706-14716 View Article PubMed/NCBI
  132. Karamese M, Altoparlak U, Turgut A, Aydogdu S, Karamese SA. The relationship between adenovirus-36 seropositivity, obesity and metabolic profile in Turkish children and adults. Epidemiol Infect 2015;143(16):3550-3556 View Article PubMed/NCBI
  133. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334(5):292-295 View Article PubMed/NCBI
  134. Sapunar J, Fonseca L, Molina V, Ortiz E, Barra MI, Reimer C, et al. Adenovirus 36 seropositivity is related to obesity risk, glycemic control, and leptin levels in Chilean subjects. Int J Obes (Lond) 2020;44(1):159-166 View Article PubMed/NCBI
  135. Sohrab SS, Kamal MA, Atkinson RL, Alawi MM, Azhar EI. Viral infection and obesity: current status and future prospective. Curr Drug Metab 2017;18(9):798-807 View Article PubMed/NCBI
  136. Rogers PM, Fusinski KA, Rathod MA, Loiler SA, Pasarica M, Shaw MK, et al. Human adenovirus Ad-36 induces adipogenesis via its E4 orf-1 gene. Int J Obes (Lond) 2008;32(3):397-406 View Article PubMed/NCBI
  137. Tarantino G, Citro V, Cataldi M. Findings from studies are congruent with obesity having a viral origin, but what about obesity-related NAFLD?. Viruses 2021;13(7):1285 View Article PubMed/NCBI

Copyright © 2023 Authors. This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • © 2024 Xia & He Publishing Inc.
  • Total visits : 2640284
  • Visits today : 2290